The fact that 10% of
colorectal cancer tumors harbor BRAF V600E mutations suggested targeting BRAF as a potential
therapy. However, BRAF inhibitors have only limited single-agent efficacy in this context. The potential for combination
therapy has been shown by the BEACON trial where targeting the
EGF receptor with
cetuximab greatly increased efficacy of BRAF inhibitors in BRAF-mutant
colorectal cancer. Therefore, we explored whether efficacy of the mutant BRAF inhibitor
vemurafenib could be enhanced by cotargeting of either oncogenic WNT/β-
catenin signaling or VEGFR signaling. We find the WNT/β-
catenin inhibitors
pyrvinium,
ICG-001 and
PKF118-310 attenuate growth of
colorectal cancer cell lines in vitro with BRAF-mutant lines being relatively more sensitive.
Pyrvinium combined with
vemurafenib additively or synergistically attenuated growth of
colorectal cancer cell lines in vitro. The selective and potent VEGFR inhibitor
axitinib was most effective against BRAF-mutant
colorectal cancer cell lines in vitro, but the addition of
vemurafenib did not significantly increase these effects. When tested in vivo in animal
tumor models, both
pyrvinium and
axitinib were able to significantly increase the ability of
vemurafenib to attenuate
tumor growth in xenografts of BRAF-mutant
colorectal cancer cells. The magnitude of these effects was comparable with that induced by a combination of
vemurafenib and
cetuximab. This was associated with additive effects on release from
tumor cells and tumor microenvironment cell types of substances that would normally aid
tumor progression. Taken together, these preclinical data indicate that the efficacy of BRAF inhibitor
therapy in
colorectal cancer could be increased by cotargeting either WNT/β-
catenin or VEGFRs with small-molecule inhibitors.